A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan
文献类型：期刊论文
| 作者 | He, Yunxia1,2; Yu, Weili2; Shen, Lijuan2; Yan, Wenying1,2; Xiao, Lucheng1,2; Qi, Jinming2; Hu, Tao2 |
| 刊名 | INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
 |
| 出版日期 | 2022-12-01 |
| 卷号 | 222页码:661-670 |
| 关键词 | SARS-CoV-2 RBD Adjuvant |
| ISSN号 | 0141-8130 |
| DOI | 10.1016/j.ijbiomac.2022.09.180 |
| 英文摘要 | SARS-CoV-2 is a particularly transmissible virus that causes a severe respiratory disease known as COVID-19. Safe and effective vaccines are urgently needed to combat the COVID-19 pandemic. The receptor-binding domain (RBD) of SARS-CoV-2 spike protein elicits most neutralizing antibodies during viral infection and is an ideal antigen for vaccine development. In particular, RBD expressed by E. coli is amenable to low cost and high-yield manufacturability. The adjuvant is necessitated to improve the immunogenicity of RBD. IC28, a TLR5dependent adjuvant, is a peptide from bacterial flagellin. Mannan is a ligand of TLR-4 or TLR-2 and a polysaccharide adjuvant. Here, IC28 and mannan were both covalently conjugated with RBD from E. coli. The conjugate (RBD-IC28-M) elicited high RBD-specific IgG titers, and a neutralization antibody titer of 201.4. It induced high levels of Th1-type cytokines (IFN-gamma) and Th2-type cytokines (IL-5 and IL-10), along with high antigenicity and no apparent toxicity to the organs. The mouse sera of the RBD-IC28-M group competitively interfered with the interaction of RBD and ACE2. Thus, conjugation with IC28 and mannan additively enhanced the humoral and cellular immunity. Our study was expected to provide the feasibility to develop an affordable, easily scalable, effective vaccine SARS-CoV-2 vaccine. |
| WOS关键词 | COVID-19 ; PROTEIN ; IMMUNOGENICITY |
| 资助项目 | Beijing Natural Science Foundation ; National Natural Science Foundation of China ; National Key Research and Develop- ment Project of China ; [M21013] ; [82271869] ; [31970875] ; [2018YFA0900804] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Chemistry ; Polymer Science |
| 语种 | 英语 |
| WOS记录号 | WOS:000876880400005 |
| 出版者 | ELSEVIER |
| 资助机构 | Beijing Natural Science Foundation ; National Natural Science Foundation of China ; National Key Research and Develop- ment Project of China |
| 源URL | [http://ir.ipe.ac.cn/handle/122111/55472]  |
| 专题 | 中国科学院过程工程研究所 |
| 通讯作者 | Qi, Jinming; Hu, Tao |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing 100190, Peoples R China 2.Chinese Acad Sci, State Key Lab Biochem Engn, Inst Proc Engn, Beijing 100190, Peoples R China |
| 推荐引用方式 GB/T 7714 | He, Yunxia,Yu, Weili,Shen, Lijuan,et al. A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,2022,222:661-670. |
| APA | He, Yunxia.,Yu, Weili.,Shen, Lijuan.,Yan, Wenying.,Xiao, Lucheng.,...&Hu, Tao.(2022).A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan.INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,222,661-670. |
| MLA | He, Yunxia,et al."A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan".INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES 222(2022):661-670. |
入库方式： OAI收割
来源：过程工程研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。